Inhibition of plasma kallikrein and activated factor XII has been central to this progress, with several new treatments now available for acute angioedema attacks, including C1-INH concentrate, icatibant acetate, ecallantide, and recombinant C1-INH. The gene discussed is SERPING1; the disease is angioedema.